NXI Therapeutics Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 7

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3.88M

  • Investors
  • 10

NXI Therapeutics General Information

Description

Developer of selective immunosuppressive drugs designed to treat autoimmune diseases and transplantations. The company focuses on clinical applications in T cell-mediated autoimmune conditions and creating immunotherapies through modulation of coronin in immune cells, enabling patients and consumers with effective curing medicines.

Contact Information

Website
www.nxitherapeutics.com
Formerly Known As
NextImmune
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Spitalstrasse 41
  • 4056 Basel
  • Switzerland
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
HealthTech
Corporate Office
  • Spitalstrasse 41
  • 4056 Basel
  • Switzerland

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NXI Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Later Stage VC 18-Jun-2024 $3.88M Completed Generating Revenue
11. Accelerator/Incubator Completed Generating Revenue
10. Accelerator/Incubator 01-Jul-2022 Completed Generating Revenue
9. Accelerator/Incubator 28-Jun-2022 Completed Generating Revenue
8. Seed Round 18-May-2022 Completed Generating Revenue
7. Accelerator/Incubator 13-Sep-2021 Completed Generating Revenue
6. Grant 08-Jun-2021 Completed Generating Revenue
5. Accelerator/Incubator 23-Jun-2021 Completed Generating Revenue
4. Seed Round 11-Mar-2021 $44.1K $228K Completed Generating Revenue
3. Accelerator/Incubator 01-Jan-2020 $50.9K $184K Completed Generating Revenue
To view NXI Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

NXI Therapeutics Patents

  • 3

    Total Documents Applications and Grants

  • Total Patents Families

  • Granted

  • 3

    Pending

  • Expiring in next 12 mo

NXI Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025210193-A1 4-(hetero)aryl-7-(hetero)aryl-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-ca rboxylic acid derivatives as coronin-1 modulators Pending 03-Apr-2024
AU-2025251398-A1 4-(hetero)aryl-7-(hetero)aryl-2-methyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline-3-carboxylic acid derivatives as coronin-1 modulators Pending 03-Apr-2024
WO-2025210192-A1 Coronin-1 modulators Pending 03-Apr-2024 A61P37/02

NXI Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NXI Therapeutics Investors (10)

Investor Name Investor Type Holding Investor Since Participating Rounds
BioMedPartners Venture Capital Minority
JFG Life Sciences Foundation University Minority
Kickfund Venture Capital Minority
Gebert Rüf Foundation Accelerator/Incubator
Venturelab Accelerator/Incubator
You’re viewing 5 of 10 investors. Get the full list »

Ready to get started?

Request a free trial

NXI Therapeutics FAQs

  • When was NXI Therapeutics founded?

    NXI Therapeutics was founded in 2015.

  • Where is NXI Therapeutics headquartered?

    NXI Therapeutics is headquartered in Basel, Switzerland.

  • What is the size of NXI Therapeutics?

    NXI Therapeutics has 7 total employees.

  • What industry is NXI Therapeutics in?

    NXI Therapeutics’s primary industry is Drug Discovery.

  • Is NXI Therapeutics a private or public company?

    NXI Therapeutics is a Private company.

  • What is NXI Therapeutics’s current revenue?

    The current revenue for NXI Therapeutics is .

  • How much funding has NXI Therapeutics raised over time?

    NXI Therapeutics has raised $4.51M.

  • Who are NXI Therapeutics’s investors?

    BioMedPartners, JFG Life Sciences Foundation, Kickfund, Gebert Rüf Foundation, and Venturelab are 5 of 10 investors who have invested in NXI Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process